ArticleBMC nephrology2013
Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosis.
Article in BMC nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Preventative effect of montelukast in mild to moderate contrast-induced acute kidney injury in rats via NADPH oxidase 4, p22phox and nuclear factor kappa-B expressions.International urology and nephrology · 2025Article
- Mechanism of xanthine oxidase in flap ischemia-reperfusion injury and advances in targeted therapy: a mini review.Frontiers in physiology · 2025Review
- Management of Pediatric Urolithiasis in an Italian Tertiary Referral Center: A Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Impact of hyperbilirubinemia associated acute kidney injury on chronic kidney disease after aortic arch surgery: a retrospective study with follow-up of 1-year.Journal of cardiothoracic surgery · 2022Article
- Role of (pro)renin receptor in cyclosporin A-induced nephropathy.American journal of physiology. Renal physiology · 2022Article
- Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease.Biomedicines · 2022Review
- A prediction model for acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2022Article
- Cholemic Nephropathy as Cause of Acute and Chronic Kidney Disease. Update on an Under-Diagnosed Disease.Life (Basel, Switzerland) · 2021Article
- Metabolomics analysis of the serum from children with urolithiasis using UPLC-MS.Clinical and translational science · 2021Observational
- Clinical impact of serum bilirubin levels on kidney transplant outcomes.Scientific reports · 2021Article
- Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.Antioxidants (Basel, Switzerland) · 2021Review
- Life-Long Hyperbilirubinemia Exposure and Bilirubin Priming PreventFrontiers in pharmacology · 2021Article
- Serum Bilirubin Is Correlated With the Progression of IgA Vasculitis With Nephritis.Frontiers in medicine · 2021Article
- The Extent of Intracellular Accumulation of Bilirubin Determines Its Anti- or Pro-Oxidant Effect.International journal of molecular sciences · 2020Article
- Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.Nature reviews. Nephrology · 2020Review
- Article
- Non-urate transporter 1, non-glucose transporter member 9-related renal hypouricemia and acute renal failure accompanied by hyperbilirubinemia after anaerobic exercise: a case report.BMC nephrology · 2019Article
- Beyond a Measure of Liver Function-Bilirubin Acts as a Potential Cardiovascular Protector in Chronic Kidney Disease Patients.International journal of molecular sciences · 2018Review
- Elevated bilirubin levels are associated with a better renal prognosis and ameliorate kidney fibrosis.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBilirubin (BIL) has been recognized as an endogenous antioxidant that shows a protective effect for cardiorenal diseases. We investigated whether administration of BIL had a protective effect on cyclosporine (CsA)-induced nephropathy (CIN), and examined the effects of BIL on the oxidative stress and apoptosis.
methodsBIL was pretreated intraperitoneally three times for a week (60 mg/kg), and CsA was injected for 4 weeks (15 mg/kg/day, subcutaneous). Proximal tubular epithelial (HK2) cells were pretreated with 0.1mg/ml of BIL for 24 hours, and then treated with 20 μM of CsA for another 24 hours.
resultsCsA induced marked increases in urine kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL) concentrations (P < 0.05). BIL reduced urine Kim-1 in CIN (P < 0.05), while urine NGAL exhibited a decreasing tendency. In CsA-treated rat kidneys, the protein expression of NOX4 and p22phox was reduced by BIL (P < 0.05). BIL ameliorated CsA-induced arteriolopathy, tubulointerstitial fibrosis, tubular injury, and the apoptosis examined by TUNEL assay (P < 0.01). In HK2 cells, BIL reduced intracellular reactive oxygen species in CsA-treated cells. CsA increased the protein expression of bax, cleaved caspase-9, caspase-3 and the activity of caspase-3; however, the anti-apoptotic bcl-2 protein was reduced. These changes were recovered by BIL (P < 0.05).
conclusionsThe direct administration of BIL protected against CsA-induced tubular injury via inhibition of oxidative stress and apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.